Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oaktree Acquisition III Life Sciences (NAS:OACC) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Oaktree Acquisition III Life Sciences's Enterprise Value for the quarter that ended in Jun. 2026 was $261.87 Mil.
Oaktree Acquisition III Life Sciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oaktree Acquisition III Life Sciences EV-to-EBIT Related Terms
Oaktree Acquisition III Life Sciences EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oaktree Acquisition III Life Sciences EV-to-EBIT Chart
Oaktree Acquisition III Life Sciences Annual Data
Trend
Dec24
Dec25
EV-to-EBIT
0.00
-216.28
Oaktree Acquisition III Life Sciences Quarterly Data
For the Shell Companies subindustry, Oaktree Acquisition III Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oaktree Acquisition III Life Sciences EV-to-EBIT vs Diversified Financial Services Industry
For the Diversified Financial Services industry and Financial Services sector, Oaktree Acquisition III Life Sciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Oaktree Acquisition III Life Sciences's EV-to-EBIT falls into.
Oaktree Acquisition III Life Sciences's current Enterprise Value is $262.85 Mil.
Oaktree Acquisition III Life Sciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oaktree Acquisition III Life Sciences (OACC) has a EV-to-EBIT of -219.04 as of Aug. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Oaktree Acquisition III Life Sciences and its competitors. According to the industry distribution chart, Oaktree Acquisition III Life Sciences ranks #999999 out of 143 companies in the Diversified Financial Services industry.
Is Oaktree Acquisition III Life Sciences' EV-to-EBIT too high?
Oaktree Acquisition III Life Sciences' current EV-to-EBIT is -219.04. Based on the distribution chart, Oaktree Acquisition III Life Sciences ranks #999999 out of 143 companies in the Diversified Financial Services industry, which is in the bottom quartile relative to peers. Overall, Oaktree Acquisition III Life Sciences has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Oaktree Acquisition III Life Sciences' EV-to-EBIT compare to DMAA and FACT?
According to the Diversified Financial Services industry distribution chart, Oaktree Acquisition III Life Sciences ranks #999999 out of 143 companies for EV-to-EBIT. This places Oaktree Acquisition III Life Sciences in the lower half of its industry. The industry median EV-to-EBIT is 4.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Diversified Financial Services company?
The median EV-to-EBIT among Diversified Financial Services companies is 4.35, based on 143 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Oaktree Acquisition III Life Sciences and its competitors. For the Diversified Financial Services industry, the median EV-to-EBIT is 4.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oaktree Acquisition III Life Sciences's current EV-to-EBIT is -219.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oaktree Acquisition III Life Sciences stock overvalued right now?
Oaktree Acquisition III Life Sciences (OACC) has a current EV-to-EBIT of -219.04. The current EV-to-EBIT is -219.04. Oaktree Acquisition III Life Sciences' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Oaktree Acquisition III Life Sciences (OACC), the current EV-to-EBIT is -219.04 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OACC has been successfully added to your 
